Search
Displaying 81–90 of 689 for “retinitis clinical trial”
-
Research News
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
Research NewsThe company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
Research NewsThe expanded Phase 1/2/3 shortens time to potential FDA approval.
-
Luxa Reports Vision Improvements in Clinical Trial of its RPE Stem Cell Therapy for Dry AMD
Research NewsPatients with worse vision at trial enrollment had greatest vision improvements.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
Retinal Patch Performs Promisingly in Clinical Trial for Dry AMD Patients
Research NewsRegenerative Patch Technologies, a company developing stem-cell-derived treatments for people with retinal diseases, has reported encouraging results for the first five patients with advanced, dry age-related macular degeneration (AMD) participating in a Phase I/IIa clinical trial for its therapy – a patch comprised of a layer of retinal pigment epithelial (RPE) cells on a synthetic scaffold.
-
Vision Improvements Reported in ProQR's Clinical Trial for LCA10 Treatment
Research NewsThe company reported that 60 percent of subjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course. The treatment was also safe for patients.
